Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities

Lefamulin efficacy and safety in a pooled phase 3 clinical trial population with community-acquired bacterial pneumonia and common clinical comorbidities

Abstract Background Lefamulin, a first-in-class pleuromutilin antibiotic approved for intravenous and oral use in adults with community-acquired bacterial pneumonia (CABP), was noninferior to moxifloxacin in the Lefamulin Evaluation Against Pneumonia (LEAP) 1 intravenous-to-oral switch study and the...

Full description

Bibliographic Details
Main Authors: Thomas M. File, Elizabeth Alexander, Lisa Goldberg, Anita F. Das, Christian Sandrock, Susanne Paukner, Gregory J. Moran
Format: Article
Language:English
Published: BMC 2021-05-01
Series:BMC Pulmonary Medicine
Subjects:
Antibiotic
Clinical response
Lefamulin
Pleuromutilin
Pneumonia
Online Access:https://doi.org/10.1186/s12890-021-01472-z

Internet

https://doi.org/10.1186/s12890-021-01472-z

Similar Items